A Phase IIIB, Randomized, Open-Label, Parallel Group, Multi-Center, Non-Inferiority, 24-Week Study to Evaluate the Safety, Efficacy and Tolerability of Switching From a 200mg Ritonavir-Boosted Regimen of LEXIVA (700mg/100mg BID or 1400mg/200mg QD) to a Once-Daily, 100mg Ritonavir-Boosted Regimen of LEXIVA (1400mg/100mg QD)

Trial Profile

A Phase IIIB, Randomized, Open-Label, Parallel Group, Multi-Center, Non-Inferiority, 24-Week Study to Evaluate the Safety, Efficacy and Tolerability of Switching From a 200mg Ritonavir-Boosted Regimen of LEXIVA (700mg/100mg BID or 1400mg/200mg QD) to a Once-Daily, 100mg Ritonavir-Boosted Regimen of LEXIVA (1400mg/100mg QD)

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2010

At a glance

  • Drugs Fosamprenavir; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors; Ritonavir
  • Indications HIV-1 infections
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms LESS
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Feb 2009 Actual patient numbers (211) added as reported by ClinicalTrials.gov.
    • 22 Nov 2008 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top